Ouch: Eli Lilly is walking away from Adocia deal and its ultra-fast insulin — for the second time
A little more than two years ago, Eli Lilly admitted it had made a big mistake in dumping Adocia (Paris:ADOC) and their pact on the biotech’s ultra-fast-acting insulin formulation, Biochaperone Lispro. That original deal was completed with only $10 million for the upfront and $155 million in milestones. To get back in after promising mid-stage studies, Lilly had to pay $50 million up front and offered more than three times the original amount in milestones – plus R&D support.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
